But PrEP is only reaching
a small proportion of those who could benefit from it. Among the estimated 1.1 million people nationwide who are potential candidates for
PrEP, only 8% are receiving it, according to new data from the US Centers for
Disease Control and Prevention (CDC). Although African Americans and Latinos make up about two-thirds
of people who stand to benefit from PrEP, they are much less likely than white people to be using it.

AIDSVu numbers

The US Food and Drug Administration
approved Truvada
(tenofovir/emtricitabine) for HIV prevention in July 2012. It has been
difficult to estimate the total number of people using PrEP because this
information is not centrally collected.

For the past several years Gilead Sciences, the maker of Truvada, has been reporting PrEP use
estimates based on surveys of commercial pharmacies. At the International AIDS Society Conference on HIV Science last summer, Gilead researchers reported that an estimated 120,000 people had ever started Truvada for PrEP since 2012.

Now, Gilead has teamed up with researchers at Emory University's Rollins
School of Public Health to make the latest PrEP numbers available via AIDSVu, an interactive online
map of the US HIV/AIDS epidemic.

SHA collects data from more than 54,000 pharmacies, 1500 hospitals, 800
outpatient facilities and 80,000 physician practices across the US. It includes
prescriptions paid for in cash or by private insurance, Medicaid or Medicare
(programmes for low-income people and seniors, respectively) or patient
assistance programmes. It does not include PrEP obtained from other sources
including demonstration studies, military and veterans' health systems and
managed care providers that run their own pharmacies (such as Kaiser Permanente).
The CDC estimates that 85 to 90% of PrEP prescriptions are filled at commercial
pharmacies.

The data released this week indicate that a total of 77,120 people were
using PrEP in 2016, up from 8768 in 2012. This represents a 73% average annual
increase, or a cumulative increase of 877% over the entire four-year period.
But behind these overall numbers lie some notable demographic and geographic
disparities.

Men accounted for 93% of PrEP users in 2016. Although
women account for about 19% of all new HIV diagnoses in the US, they make up
only 7% of PrEP users. About two-thirds of PrEP users are in the 25-to-44
age range, a group that accounted for just over half of new diagnoses. While 21% of new diagnoses are in people under the age of 25, only 11%
of PrEP users are in this age group.

In terms of geography, the rate of PrEP use in the Northeast region was around twice that of the West,
South or Midwest (47.4, 28.1, 22.6 and 23.5 users per 100,000 people,
respectively). Although just over half of all new HIV diagnoses occurred in
the south, this region was home to only 30% of PrEP
users.

After adjusting for population size, New York,
Massachusetts, Rhode Island, Washington and Illinois had the highest PrEP usage
rates.

"We hope that the newly available data on AIDSVu will allow health
departments, elected officials, medical professionals
and community leaders to better understand and visualize the realities of who
has access to this important prevention tool so they can develop programs and
policies to decrease barriers," commented AIDSVu principal scientist
Patrick Sullivan.

In
a poster presented at CROI, Sullivan's team looked at the distribution of PrEP
users and compared it to the need for PrEP based on where new HIV infections
are occurring. Using US census data and HIV case surveillance data from the
CDC, they calculated a "PrEP-to-need" ratio, dividing the number of
PrEP prescriptions by the number of new HIV diagnoses (both per 100,000
people). A higher ratio means better PrEP coverage for those who need it.

The
researchers reported that around 61,300 individuals nationwide had active
PrEP prescriptions in the second
quarter of 2017, or 23.0 per 100,000 people. (Not everyone who starts PrEP
stays on it over time, so the quarterly number is smaller than the annual total
reflected in the AIDSVu figures described above.) There were 15.0 new HIV
diagnoses per 100,000 people nationwide, giving a PrEP-to-need ratio of 1.5.

The
Northeast, which had the highest rate of PrEP use at 38.5 and 13.3 new HIV
diagnoses per 100,000, had the highest PrEP-to-need ratio, at 2.9. The South
had a low PrEP use rate of 18.8 and a high diagnosis rate of 20.9 per 100,000,
giving the lowest PrEP-to-need ratio, at 0.9. The Midwest and West fell in
between, with PrEP-to-need ratios of 2.1 and 1.8, respectively.

Sullivan's
team also calculated PrEP use and PrEP-to-need ratios for various demographic groups.
Women had a PrEP usage rate of 2.0 and a new diagnosis rate of 5.5 per 100,000,
giving a PrEP-to-need ratio of 0.4, indicating great unmet need. In comparison,
men had a PrEP usage rate of 45.0 and a diagnosis rate of 24.9 per 100,000, for
a PrEP-to-need ratio of 1.8. People age 24 and younger or 55 and older had
lower PrEP-to-need ratios than those between these ages.

States
with a higher proportion of people living in poverty, more people without
health insurance and those that did not implement Medicaid expansion under the
Affordable Care Act – which provides coverage for more people further up the
income scale – had lower rates of PrEP usage and lower PrEP-to-need ratios.

"This
study estimates that only 5% of the 1.2 million persons indicated for PrEP are
potentially receiving PrEP protection, demonstrating a need to scale up PrEP
among all groups and in all regions," the researchers concluded.

Need for PrEP higher among black Americans

It is widely acknowledged that African Americans have the highest HIV
incidence and lowest PrEP usage rates, but this is hard to quantify because
prescription data often do not include information about race or ethnicity.

The Emory team made a rough estimate based on the proportion of African
Americans living in a state. They found that states with less than 3% African
Americans had a PrEP usage rate of 12.0 and an HIV diagnosis rate of 7.0,
yielding a PrEP-to-need ratio of 1.7. In contrast, states with 16% or more
black people had a PrEP usage rate of 20.0 and a diagnosis rate of 22.1, for a
PrEP-to-need ratio of 0.9.

In another analysis, Dawn Smith of the CDC's Division of HIV/AIDS
Prevention presented
results of a detailed analysis of PrEP use and need by race/ethnicity, combining
data on risk behaviours, new HIV diagnoses at the national and state level, and
Truvada prescriptions filled at commercial pharmacies.

The new state-level estimates suggest that 1.14
million Americans were at substantial risk for HIV and eligible for PrEP in
2015 according to CDC guidelines – down
slightly from the earlier national
figure of 1.23 million. Of these, 44% were black,
26% were white and 25% were Latino. However, only about 90,000 PrEP
prescriptions were filled between September 2015 and August 2016, Smith
reported.

Approximately 500,000 African Americans and nearly
300,000 Latinos nationwide could potentially benefit from PrEP, but only 7000
prescriptions were known to have been filled for black people and 7600 for Latinos
during this period. That is, only 1% of eligible African Americans and about 3% of Latinos
were using PrEP. Even with missing racial/ethnic data for about a third of PrEP
prescriptions, this reveals a substantial unmet need.

There was
a smaller but still considerable gap between the number of white people who
could potentially benefit from PrEP (300,000) and the number who received
prescriptions (42,000), indicating that just 14% of those eligible were using
it.

CDC
estimates that 38% of gay and bisexual men who are eligible for PrEP are black,
64% of eligible heterosexuals are black, and 37% of eligible people
who inject drugs are
black.

"African Americans make up nearly half of people
who could potentially benefit from PrEP, but by far they are the least likely
to have a prescription," Smith told reporters at a CROI press briefing.
"After six years, we're nowhere near tapping the full potential of PrEP as
a hugely powerful HIV prevention tool."

NAM's news coverage of the 2018 Conference on Retroviruses and Opportunistic Infections has been supported by a grant from Gilead Sciences Europe Ltd.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends
checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member
of your healthcare team for advice tailored to your situation.